Literature DB >> 22194464

SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.

Alicia M Cock-Rada1, Souhila Medjkane, Natacha Janski, Nadhir Yousfi, Martine Perichon, Marie Chaussepied, Johanna Chluba, Gordon Langsley, Jonathan B Weitzman.   

Abstract

Upregulation of the matrix metalloproteinase (MMP)-9 plays a central role in tumor progression and metastasis by stimulating cell migration, tumor invasion, and angiogenesis. To gain insights into MMP-9 expression, we investigated its epigenetic control in a reversible model of cancer that is initiated by infection with intracellular Theileria parasites. Gene induction by parasite infection was associated with trimethylation of histone H3K4 (H3K4me3) at the MMP-9 promoter. Notably, we found that the H3K4 methyltransferase SMYD3 was the only histone methyltransferase upregulated upon infection. SMYD3 is overexpressed in many types of cancer cells, but its contributions to malignant pathophysiology are unclear. We found that overexpression of SMYD3 was sufficient to induce MMP-9 expression in transformed leukocytes and fibrosarcoma cells and that proinflammatory phorbol esters further enhanced this effect. Furthermore, SMYD3 was sufficient to increase cell migration associated with MMP-9 expression. In contrast, RNA interference-mediated knockdown of SMYD3 decreased H3K4me3 modification of the MMP-9 promoter, reduced MMP-9 expression, and reduced tumor cell proliferation. Furthermore, SMYD3 knockdown also reduced cellular invasion in a zebrafish xenograft model of cancer. Together, our results define SMYD3 as an important new regulator of MMP-9 transcription, and they provide a molecular link between SMYD3 overexpression and metastatic cancer progression. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22194464      PMCID: PMC3299564          DOI: 10.1158/0008-5472.CAN-11-1052

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Acetylation of histones and transcription-related factors.

Authors:  D E Sterner; S L Berger
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

2.  Matrix metalloproteinases mediate the metastatic phenotype of Theileria annulata-transformed cells.

Authors:  R E Adamson; F R Hall
Journal:  Parasitology       Date:  1996-11       Impact factor: 3.234

3.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Authors:  Mario F Fraga; Esteban Ballestar; Ana Villar-Garea; Manuel Boix-Chornet; Jesus Espada; Gunnar Schotta; Tiziana Bonaldi; Claire Haydon; Santiago Ropero; Kevin Petrie; N Gopalakrishna Iyer; Alberto Pérez-Rosado; Enrique Calvo; Juan A Lopez; Amparo Cano; Maria J Calasanz; Dolors Colomer; Miguel Angel Piris; Natalie Ahn; Axel Imhof; Carlos Caldas; Thomas Jenuwein; Manel Esteller
Journal:  Nat Genet       Date:  2005-03-13       Impact factor: 38.330

4.  Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons.

Authors:  B Bauvois; J Dumont; C Mathiot; J-P Kolb
Journal:  Leukemia       Date:  2002-05       Impact factor: 11.528

5.  Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma.

Authors:  Hee Kyung Kim; Hong Zhang; Hui Li; Tsung-Teh Wu; Stephen Swisher; Donggou He; Lizhi Wu; Jianmin Xu; Craig A Elmets; Mohammad Athar; Xìao-chun Xu; Hui Xu
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

6.  Theileria parva infection induces autocrine growth of bovine lymphocytes.

Authors:  D A Dobbelaere; T M Coquerelle; I J Roditi; M Eichhorn; R O Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

7.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.

Authors:  Ryuji Hamamoto; Yoichi Furukawa; Masashi Morita; Yuko Iimura; Fabio Pittella Silva; Meihua Li; Ryuichiro Yagyu; Yusuke Nakamura
Journal:  Nat Cell Biol       Date:  2004-07-04       Impact factor: 28.824

Review 8.  Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9).

Authors:  Philippe E Van den Steen; Bénédicte Dubois; Inge Nelissen; Pauline M Rudd; Raymond A Dwek; Ghislain Opdenakker
Journal:  Crit Rev Biochem Mol Biol       Date:  2002-12       Impact factor: 8.250

9.  The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.

Authors:  Cheng Liu; Xiaolei Fang; Zheng Ge; Marit Jalink; Satoru Kyo; Magnus Björkholm; Astrid Gruber; Jan Sjöberg; Dawei Xu
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

10.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

Authors:  H Sato; M Seiki
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

View more
  72 in total

1.  Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Authors:  Chuhui Huang; Si Si Liew; Grace R Lin; Anders Poulsen; Melgious J Y Ang; Brian C S Chia; Sin Yin Chew; Zekui P Kwek; John L K Wee; Esther H Ong; Priya Retna; Nithya Baburajendran; Rong Li; Weixuan Yu; Xiaoying Koh-Stenta; Anna Ngo; Sravanthy Manesh; Justina Fulwood; Zhiyuan Ke; Hwa Hwa Chung; Sugunavathi Sepramaniam; Xin Hui Chew; Nurul Dinie; May Ann Lee; Yun Shan Chew; Choon Bing Low; Vishal Pendharkar; Vithya Manoharan; Susmitha Vuddagiri; Kanda Sangthongpitag; Joma Joy; Alex Matter; Jeffrey Hill; Thomas H Keller; Klement Foo
Journal:  ACS Med Chem Lett       Date:  2019-05-23       Impact factor: 4.345

2.  Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.

Authors:  Virendra Singh; Laishram C Singh; Avninder P Singh; Jagannath Sharma; Bibhuti B Borthakur; Arundhati Debnath; Avdhesh K Rai; Rup K Phukan; Jagadish Mahanta; Amal C Kataki; Sujala Kapur; Sunita Saxena
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Knockdown of Rho-associated protein kinase 1 suppresses proliferation and invasion of glioma cells.

Authors:  Peng Zhang; Ying Lu; Xue You Liu; Yu Hua Zhou
Journal:  Tumour Biol       Date:  2014-09-30

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

5.  Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase.

Authors:  Pawel K Mazur; Or Gozani; Julien Sage; Nicolas Reynoird
Journal:  Transl Cancer Res       Date:  2016-06       Impact factor: 1.241

6.  Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.

Authors:  Cheng-Lin Zhu; Qiang Huang
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

7.  SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.

Authors:  Qing-Qing Dong; Qiu-Tong Wang; Lei Wang; Ya-Xin Jiang; Mei-Ling Liu; Hai-Jie Hu; Yong Liu; Hao Zhou; Hong-Peng He; Tong-Cun Zhang; Xue-Gang Luo
Journal:  Food Sci Biotechnol       Date:  2018-03-22       Impact factor: 2.391

Review 8.  Zebrafish Discoveries in Cancer Epigenetics.

Authors:  Yelena Chernyavskaya; Brandon Kent; Kirsten C Sadler
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

9.  MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway.

Authors:  Nan Li; Anliu Tang; Shuo Huang; Zeng Li; Xiayu Li; Shourong Shen; Jian Ma; Xiaoyan Wang
Journal:  Mol Cell Biochem       Date:  2013-04-25       Impact factor: 3.396

Review 10.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.